https://www.iddo.org/document/artesunate-amodiaquine-dose-impact-study-group-acknowledments 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/document/artemether-lumefantrine-dose-impact-study-group-acknowledgements 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/document/country-antimalarial-drug-policies 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/document/interview-paul-newton 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/document/toolkit-v3 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/document/drug-abbreviations 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/document/pharmacology-questionnaire 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/document/non-compartmental-analysis 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/document/primaquine-literature-review-library-studies 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/document/primaquine-literature-review-efficacy-forest-plots-1-4 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/document/primaquine-literature-review-research-priorities 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/document/study-report-summary-pv 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/document/sample-data 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/document/pce-methodology 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/document/extracted-data-p-vivax-antimalarial-efficacy-study-sites 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/document/pce-example-automated-report 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/document/wwarn-agenda-activities-astmh-2013 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/document/rsa-training-workshop-agenda 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/document/pce-terms-use 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/document/study-group-summary-risk-factors-affecting-dosing-efficacy-astmh-2013 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/document/pce-csv-file-template 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/document/pharmacology-pkpd-day-7-lumefantrine-statistical-analysis-plan 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/document/asaq-dose-impact-study-group-presentation 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/document/dp-dose-impact-study-group-presentation 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/document/al-dose-impact-study-group-presentation 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/document/gametocyte-carriage-study-group-statistical-analysis-plan 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/document/racing-against-time-protecting-gains-achieved-malaria-control-against-drug-resistance 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/document/medicine-quality-brochure 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/document/alternative-strategies-prevent-malaria-pregnancy-study-group-references 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/document/data-access-committee-process-selection 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/document/terms-data-access 2024-07-25T16:42:55+01:00 0.5 https://www.iddo.org/document/vivax-recurrence-study-group-statistical-analysis-plan 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/document/vivax-haematology-study-group-statistical-analysis-plan 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/document/newton-fund-workshop-nairobi-january-2018 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/document/k13-and-clinical-phenotype-study-group-statistical-analysis-plan 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/document/patient-book-extract 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/document/vitro-sample-study-report 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/document/wwarn-publication-library-clinical-trials-1960-2017 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/document/polymorphisms-plasmodium-falciparum-chloroquine-resistance-transporter-and-multidrug 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/document/statistical-analysis-plan-wwarn-vivax-haematology-study-group 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/document/publication-policy 2025-10-09T14:48:52+01:00 0.5 https://www.iddo.org/document/subpatent-malaria-study-group-data-analysis-plan 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/document/p-vivax-drug-efficacy-protocol-template 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/document/trial-registration 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/document/pharmacology-data-management-and-statistical-analysis-plan 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/document/vitro-data-management-and-statistical-analysis-plan 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/document/molecular-data-management-and-statistical-analysis-plan 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/document/data-handling-and-analysis-convention-ecg-data-malaria 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/document/statistical-analysis-plan-dha-pqp-dose-impact-study-group-version-19 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/document/studies-day-3-parasitaemia-positivity-rates-above-10 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/document/medquarg-guidelines 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/document/royal-society-tropical-medicine-2012-innovative-monitoring-schemes 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/document/wwarn-and-partner-sessions-astmh-2014 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/document/malaria-2014-unprecedented-opportunity-dawn-new-era 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/document/al-dose-impact-study-group-presentation-0 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/document/building-electronic-data-management-system-using-wwarn-annotated-case-record-form 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/document/primaquine-methaemoglobin-study-group-statistical-analysis-plan-0 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/document/wwarn-primaquine-indian-region-study-group-statistical-analysis-plan-0 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/document/act-malaria-and-malnutrition-study-group-statistical-analysis-plan-0 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/document/vivax-and-ovale-paediatric-primaquine-study-groups-statistical-analysis-plan 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/external-publication/post-discharge-malaria-chemoprevention-children-admitted-severe-anaemia 2023-12-18T16:37:06+00:00 0.5 https://www.iddo.org/document/wwarn-clinical-trials-publication-library-download 2026-04-30T13:17:12+01:00 0.5 https://www.iddo.org/external-publication/lymphatic-filariasis-treatment-study-landscape-systematic-review-study 2024-01-26T10:06:03+00:00 0.5 https://www.iddo.org/procedure/identifying-critical-suppliers-trial-services 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/procedure/pre-trial-site-assessment 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/procedure/collection-samples-mefloquine-carboxymefloquine-pharmacology-analysis 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/document/protocol-first-trimester-burden 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/external-publication/uncertain-role-substandard-and-falsified-medicines-emergence-and-spread 2024-02-16T09:35:51+00:00 0.5 https://www.iddo.org/external-publication/repurposing-rapid-diagnostic-tests-detect-falsified-vaccines-supply-chains 2024-03-13T11:27:51+00:00 0.5 https://www.iddo.org/document/pyrogenic-clinical-trials-statistical-analysis-plan 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/external-publication/forensic-investigation-falsified-antimalarials-using-isotope-ratio-mass 2024-02-20T09:49:12+00:00 0.5 https://www.iddo.org/external-publication/does-acute-malnutrition-young-children-increase-risk-treatment-failure 2024-03-14T15:55:30+00:00 0.5 https://www.iddo.org/external-publication/systematic-review-and-geospatial-modeling-molecular-markers-resistance 2024-04-09T15:15:05+01:00 0.5 https://www.iddo.org/document/case-report-form-chagas-disease 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/external-publication/post-kala-azar-dermal-leishmaniasis-pkdl-drug-efficacy-study-landscape 2024-04-22T14:04:51+01:00 0.5 https://www.iddo.org/external-publication/comparison-who-versus-national-covid-19-therapeutic-guidelines-across-world 2024-05-01T16:27:29+01:00 0.5 https://www.iddo.org/tool/covid-19-living-systematic-review-trials 2024-05-29T09:46:55+01:00 0.5 https://www.iddo.org/external-publication/blood-transfusion-care-patients-visceral-leishmaniasis-review-practices 2024-06-07T16:34:12+01:00 0.5 https://www.iddo.org/document/antimicrobial-resistance-data-inventory 2026-04-13T16:33:35+01:00 0.5 https://www.iddo.org/external-publication/design-conduct-analysis-and-reporting-therapeutic-efficacy-studies-visceral 2024-07-11T10:06:53+01:00 0.5 https://www.iddo.org/document/statistical-analysis-plan-vivax-paediatric-primaquine 2024-07-24T10:28:30+01:00 0.5 https://www.iddo.org/external-publication/non-malarial-febrile-illness-systematic-review-published-aetiological-1 2024-08-21T14:17:07+01:00 0.5 https://www.iddo.org/external-publication/using-matrix-assisted-laser-desorption-ionisation-mass-spectrometry-combined 2024-12-24T12:57:53+00:00 0.5 https://www.iddo.org/document/iddo-data-use-agreement 2024-09-13T14:11:53+01:00 0.5 https://www.iddo.org/external-publication/primaquine-uncomplicated-plasmodium-vivax-malaria-children-younger-15-years 2024-11-13T11:45:44+00:00 0.5 https://www.iddo.org/external-publication/methaemoglobin-surrogate-marker-primaquine-antihypnozoite-activity-plasmodium 2024-11-13T11:45:38+00:00 0.5 https://www.iddo.org/external-publication/modeling-within-host-dynamics-plasmodium-vivax-hypnozoite-activation-0 2025-01-02T17:13:04+00:00 0.5 https://www.iddo.org/external-publication/identifying-falsified-covid-19-vaccines-analysing-vaccine-vial-label-and 2025-01-30T12:30:13+00:00 0.5 https://www.iddo.org/external-publication/safety-and-efficacy-single-dose-primaquine-interrupt-plasmodium-falciparum 2025-04-24T09:54:14+01:00 0.5 https://www.iddo.org/systematic-review-design-and-analysis-antileishmanial-clinical-efficacy-studies 2025-03-13T11:58:29+00:00 0.5 https://www.iddo.org/serious-adverse-events-and-mortality-following-antileishmanial-chemotherapy 2024-11-13T11:59:44+00:00 0.5 https://www.iddo.org/visceral-leishmaniasis-pregnancy-systematic-review-literature 2024-11-13T11:45:56+00:00 0.5 https://www.iddo.org/gender-disparity-patients-enrolled-clinical-trials-visceral-leishmaniasis-systematic-review-and 2024-11-13T11:46:26+00:00 0.5 https://www.iddo.org/host-parasite-and-drug-determinants-therapeutic-responses 2025-03-13T11:41:18+00:00 0.5 https://www.iddo.org/anaemia-among-patients-visceral-leishmaniasis-and-haematological-dynamics-post-treatment 2025-03-13T11:40:48+00:00 0.5 https://www.iddo.org/olamalu-test-study-group 2021-03-16T15:11:58+00:00 0.5 https://www.iddo.org/estimating-proportion-relapse-following-treatment-visceral-leishmaniasis-meta-analysis-published 2025-03-13T11:52:13+00:00 0.5 https://www.iddo.org/pharmacokinetic-analysis-nifurtimox-and-benznidazole-treatment-chagas-disease 2024-11-13T11:46:14+00:00 0.5 https://www.iddo.org/factors-associated-effectiveness-antibiotic-mass-drug-administration-mda-ethiopia-and-niger 2024-11-13T11:46:09+00:00 0.5 https://www.iddo.org/primaquine-methaemoglobin-study-group 2025-12-10T08:56:14+00:00 0.5 https://www.iddo.org/clinical-trials-methodology-study-group-p-falciparum 2024-09-19T14:06:39+01:00 0.5 https://www.iddo.org/wwarn/working-together/study-groups/alternative-strategies-prevent-malaria-pregnancy-study-group-0 2024-09-19T14:06:39+01:00 0.5 https://www.iddo.org/wwarn/working-together/study-groups/dp-dose-impact-study-group 2024-09-19T14:06:39+01:00 0.5 https://www.iddo.org/wwarn/working-together/study-groups/low-dose-primaquine-efficacy-and-safety-study-groups 2025-03-11T09:50:56+00:00 0.5 https://www.iddo.org/wwarn/working-together/study-groups/white-blood-cell-count-malaria-study-group 2024-11-13T11:46:29+00:00 0.5 https://www.iddo.org/wwarn/working-together/study-groups/piperaquine-cardiac-safety-study-group 2025-03-11T09:55:16+00:00 0.5 https://www.iddo.org/wwarn/working-together/study-groups/amodiaquine-pkpd-study-group 2024-09-19T14:06:39+01:00 0.5 https://www.iddo.org/wwarn/working-together/study-groups/falciparum-haematology-study-group 2025-03-11T09:56:24+00:00 0.5 https://www.iddo.org/wwarn/working-together/study-groups/first-trimester-safety-acts-study-group 2025-03-20T11:14:37+00:00 0.5 https://www.iddo.org/wwarn/working-together/study-groups/vivax-after-falciparum-study-group 2025-03-11T09:52:55+00:00 0.5 https://www.iddo.org/wwarn/working-together/study-groups/intermittent-preventive-treatment-pregnancy-iptp-and-sp-resistance 2024-11-13T11:45:36+00:00 0.5 https://www.iddo.org/wwarn/working-together/study-groups/malaria-pregnancy-treatment-efficacy-study-group 2025-03-20T14:08:04+00:00 0.5 https://www.iddo.org/wwarn/working-together/study-groups/plasmodium-vivax-fever-study-group 2025-05-30T13:16:29+01:00 0.5 https://www.iddo.org/wwarn/working-together/study-groups/alternative-drugs-and-strategies-prevent-malaria-pregnancy-study-group 2024-09-19T14:06:39+01:00 0.5 https://www.iddo.org/wwarn/working-together/study-groups/vivax-adherence-study-group-0 2024-11-13T11:45:36+00:00 0.5 https://www.iddo.org/wwarn/working-together/study-groups/parasite-clearance-study-group 2024-09-19T14:06:39+01:00 0.5 https://www.iddo.org/wwarn/working-together/study-groups/vivax-and-ovale-paediatric-primaquine-gastrointestinal-tolerability 2025-06-09T14:33:35+01:00 0.5 https://www.iddo.org/wwarn/working-together/study-groups/act-malaria-and-malnutrition-study-group 2024-11-13T11:46:36+00:00 0.5 https://www.iddo.org/wwarn/working-together/study-groups/piperaquine-pkpd-study-group 2024-09-19T14:06:39+01:00 0.5 https://www.iddo.org/wwarn/working-together/study-groups/malaria-pregnancy-infant-study-group 2024-09-19T14:06:39+01:00 0.5 https://www.iddo.org/wwarn/working-together/study-groups/aq-post-treatment-prophylaxis-study-group 2024-09-19T14:06:39+01:00 0.5 https://www.iddo.org/wwarn/working-together/study-groups/paediatric-single-low-dose-primaquine-efficacy-study-group 2026-03-25T11:47:24+00:00 0.5 https://www.iddo.org/wwarn/working-together/study-groups/act-africa-baseline-study-group 2024-11-13T11:45:56+00:00 0.5 https://www.iddo.org/wwarn/working-together/study-groups/lumefantrine-pkpd-study-group 2024-11-13T11:46:26+00:00 0.5 https://www.iddo.org/wwarn/working-together/study-groups/vivax-and-ovale-paediatric-primaquine-haematological-safety-study 2025-06-09T14:34:44+01:00 0.5 https://www.iddo.org/wwarn/working-together/study-groups/ivermectin-exposure-small-children-study-group-0 2024-09-19T14:06:39+01:00 0.5 https://www.iddo.org/wwarn/working-together/study-groups/aqal-molecular-marker-study-group 2024-09-19T14:06:39+01:00 0.5 https://www.iddo.org/wwarn/working-together/study-groups/molecular-markers-resistance-west-africa-study-group 2024-09-19T14:06:39+01:00 0.5 https://www.iddo.org/wwarn/working-together/study-groups/pce-data-interpretation-study-group 2024-09-19T14:06:39+01:00 0.5 https://www.iddo.org/wwarn/working-together/study-groups/primaquine-efficacy-safety-and-tolerability-study-group 2025-06-09T14:35:55+01:00 0.5 https://www.iddo.org/wwarn/working-together/study-groups/piperaquine-pharmacokinetics-pregnancy-study-group 2024-11-13T11:45:36+00:00 0.5 https://www.iddo.org/wwarn/working-together/study-groups/aq-dose-impact-study-group 2024-09-19T14:06:39+01:00 0.5 https://www.iddo.org/wwarn/working-together/study-groups/vivax-haematology-study-group 2024-09-19T14:06:39+01:00 0.5 https://www.iddo.org/wwarn/working-together/study-groups/correlation-between-k13-mutations-and-clinical-phenotype-study-group 2024-09-19T14:06:39+01:00 0.5 https://www.iddo.org/wwarn/working-together/study-groups/antimalarial-lumefantrine-poppk-study-group 2025-12-10T10:47:19+00:00 0.5 https://www.iddo.org/wwarn/working-together/study-groups/haemoglobin-haematocrit-relationship-malaria-study-group 2024-09-19T14:06:39+01:00 0.5 https://www.iddo.org/wwarn/working-together/study-groups/gametocyte-carriage-study-group 2024-09-19T14:06:39+01:00 0.5 https://www.iddo.org/wwarn/working-together/study-groups/primaquine-efficacy-and-safety-study-group 2024-09-19T14:06:39+01:00 0.5 https://www.iddo.org/wwarn/working-together/study-groups/vivax-haematological-study-group-part-2 2024-09-19T14:06:39+01:00 0.5 https://www.iddo.org/wwarn/working-together/study-groups/sp-resistance-study-group 2024-09-19T14:06:39+01:00 0.5 https://www.iddo.org/wwarn/working-together/study-groups/vivax-recurrence-study-group 2024-11-13T11:46:21+00:00 0.5 https://www.iddo.org/wwarn/working-together/study-groups/mq-dose-impact-study-group 2024-09-19T14:06:39+01:00 0.5 https://www.iddo.org/wwarn/working-together/study-groups/artemether-lumefantrine-arv-pk-study-group 2026-03-25T11:55:20+00:00 0.5 https://www.iddo.org/wwarn/working-together/study-groups/dihydroartemisinin-piperaquine-intermittent-preventive-treatment 2024-09-19T14:06:39+01:00 0.5 https://www.iddo.org/wwarn/working-together/study-groups/act-asia-baseline-study-group 2024-09-19T14:06:39+01:00 0.5 https://www.iddo.org/wwarn/working-together/study-groups/sp-resistance-data-access-group 2024-11-13T11:46:09+00:00 0.5 https://www.iddo.org/wwarn/working-together/study-groups/paediatric-single-low-dose-primaquine-safety-study-group 2024-11-13T11:46:36+00:00 0.5 https://www.iddo.org/wwarn/working-together/study-groups/sp-pkpd-study-group 2024-09-19T14:06:39+01:00 0.5 https://www.iddo.org/wwarn/working-together/study-groups/al-dose-impact-study-group 2024-09-19T14:06:39+01:00 0.5 https://www.iddo.org/wwarn/working-together/study-groups/study-group-safety-artemisinin-based-therapies-treatment-malaria-first 2024-09-19T14:06:39+01:00 0.5 https://www.iddo.org/wwarn/working-together/study-groups/vivax-and-ovale-paediatric-primaquine-efficacy-study-group 2025-06-09T14:31:50+01:00 0.5 https://www.iddo.org/wwarn/working-together/study-groups/subpatent-malaria-and-pregnancy-outcome-study-group 2025-04-09T10:41:50+01:00 0.5 https://www.iddo.org/ivermectin-pharmacokinetics-children-and-adults-study-group 2024-09-19T14:06:39+01:00 0.5 https://www.iddo.org/sub-study-impact-first-trimester-malaria-pregnancy-mother-and-infant 2024-09-19T14:06:39+01:00 0.5 https://www.iddo.org/malaria-mothers-and-babies-pregnancy-exposure-registry-mimba 2024-09-19T14:06:39+01:00 0.5 https://www.iddo.org/data-management-systems-across-malaria-clinical-trials-0 2024-09-19T14:06:39+01:00 0.5 https://www.iddo.org/cdisc-malaria-therapeutic-area-data-standard-taug-malaria 2024-09-19T14:06:39+01:00 0.5 https://www.iddo.org/molecular-and-vitro-surveillance-act-partner-drug-efficacy-greater-mekong-subregion-mivs-act 2024-09-19T14:06:39+01:00 0.5 https://www.iddo.org/tracking-resistance-artemisinin-collaboration-trac-i 2024-09-19T14:06:39+01:00 0.5 https://www.iddo.org/scoping-available-resources-and-tools 2024-11-13T11:46:21+00:00 0.5 https://www.iddo.org/smart-surveillance-4-malaria-elimination-ss4me 2024-11-13T11:46:48+00:00 0.5 https://www.iddo.org/tracking-resistance-artemisinin-collaboration-ii-trac-ii 2024-09-19T14:06:39+01:00 0.5 https://www.iddo.org/age-based-dose-regimen-optimisation 2024-09-19T14:06:39+01:00 0.5 https://www.iddo.org/correlation-between-kelch13-mutations-and-clinical-phenotype-study-group-update 2026-08-13T10:12:31+01:00 0.5 https://www.iddo.org/forensic-epidemiology-and-impact-substandard-and-falsified-antimicrobials 2024-09-19T14:06:39+01:00 0.5 https://www.iddo.org/vaccine-identity-evaluation 2024-09-19T14:06:39+01:00 0.5 https://www.iddo.org/deg-eg-project-safety-medicinal-syrups-children 2024-09-19T14:06:39+01:00 0.5 https://www.iddo.org/primaquine-indonesia-study-group 2024-11-13T11:45:56+00:00 0.5 https://www.iddo.org/renal-function-thresholds-defining-severe-malaria 2024-09-19T14:06:39+01:00 0.5 https://www.iddo.org/development-and-validation-prognostic-model-visceral-leishmaniasis-relapse 2025-03-13T11:40:25+00:00 0.5 https://www.iddo.org/safety-and-tolerability-artesunate-pyronaridine-and-artesunate-amodiaquine-treatment-uncomplicated 2025-04-09T10:27:02+01:00 0.5 https://www.iddo.org/data-integration-mathematical-modelling-antimalarial-drug-resistance-study-group 2025-03-12T12:40:35+00:00 0.5 https://www.iddo.org/individual-participant-data-meta-analysis-randomised-and-non-randomised-trials-malaria 2026-05-06T14:13:34+01:00 0.5 https://www.iddo.org/marc-se-africa-consortium 2026-06-10T12:36:48+01:00 0.5 https://www.iddo.org/safety-artemisinin-derivatives-treatment-malaria-first-trimester-pregnancy-ipd-meta-analysis-update 2025-12-11T11:36:36+00:00 0.5 https://www.iddo.org/wwarn-primaquine-latin-america-study-group-pooled-analysis-and-systematic-review-investigating 2026-04-15T10:07:09+01:00 0.5 https://www.iddo.org/wwarn-ipd-dose-response-estimation-study-group 2026-03-10T16:36:55+00:00 0.5 https://www.iddo.org/paediatric-primaquine-pharmacokinetic-pk-study-group 2026-04-13T11:09:03+01:00 0.5